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Abstract The expression of phospholipase C L 3 (PLCB3) is
low or absent in several neuroendocrine neoplasias. To investi-
gate the role of PLCB3 in the neuroendocrine tumorigenesis, we
transfected a PLCB3 construct to three neuroendocrine tumor
cell lines with a low PLCB3 expression. The growth rate and
tumorigenicity were assessed in vitro by [3H]thymidine incor-
poration and cell counting, in vivo, by xenografting to nude mice.
In vitro, PLCB3 expressing clones showed a significant growth
inhibition. The tumor weight was reduced for one of the two
xenografted PLCB3-transfected cell lines and in both, a reduced
number of proliferating (Ki-67 positive) cells was observed. This
study implies an essential role for PLCB3 in the neuroendocrine
tumorigenesis.
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1. Introduction
The PLCB3 transcript is widely expressed in human tissue
but absent in some multiple endocrine neoplasia type 1 (MEN
1)-associated as well as sporadic neuroendocrine tumors [1,2].
The PLCB3 gene is located on chromosome 11q13, which also
harbors the MEN 1 gene [3,4]. Loss of heterozygosity (LOH)
at 11q13 has been found in a low frequency in sporadic pitui-
tary tumors [5] and in about 30^70% of sporadic tumors of
the parathyroids and the endocrine pancreas. A subset of the
tumors with LOH at 11q13 exhibits mutations in the MEN 1
gene ranging from 30^58% in di¡erent studies [6^8]. LOH at
11q13 not encompassing the MEN 1 gene has been reported,
indicating the existence of another suppressor gene in the
region [9].
The speci¢c functions of the isoenzyme PLCB3 are unclear
but di¡erent members of the phospholipase family are in-
volved in signal transduction of the seven transmembrane
receptors and are widely expressed in normal tissue. Upon
binding activated subunits of heterotrimeric G proteins,
PLCB generates the second messenger molecules inositol
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) from
phosphatidylinositol 4,5-bisphosphate by hydrolysis. IP3 is in-
volved in the intracellular Ca2 homeostasis whereas DAG
activates protein kinases C (PKCs) [10]. PKCs have been
shown to be involved in cell growth activation and di¡eren-
tiation [11]. In order to investigate to what extent PLCB3 is
involved in the neuroendocrine tumorigenesis, we identi¢ed
three endocrine tumor cell lines (RIN m5F [12], BON-1 [13]
and Lcc18 [14]) with a low protein expression of PLCB3 and
stably transfected them with a PLCB3 construct [1]. The
growth rate in vitro was assessed by [3H]thymidine incorpo-
ration [15] and cell counting, tumorigenicity in vivo, by xen-
ografting to nude mice. PLCB3 expressing clones were com-
pared to, respective, wild-type (wt), an antisense control as
well as cells transfected with the vector without insert. Resto-
ration of PLCB3 expression led to a signi¢cantly reduced
growth rate in vitro for all three cell lines when compared
to, respective, wt and controls. The tumor weight in nude
mice was reduced for tumors formed by xenografted
PLCB3-transfected Lcc18 cells (RIN m5F could not be used
due to its insulin production). Further, the xenografted tu-
mors formed by both PLCB3-transfected BON-1 and Lcc18
cells show a signi¢cantly reduced staining for the proliferation
marker Ki-67 [16] and lack signs of invasive growth behavior
as compared to controls.
2. Materials and methods
2.1. Cell lines and culture conditions
Three endocrine tumor cell lines were chosen for the experiments
because of their low but variable PLCB3 protein expression (Western
blots) compared to other cell lines and normal endocrine pancreatic
tissue (data not shown). RIN-m5F (RIN) (rat insulinoma) had no
expression, BON-1 (BON) (human endocrine pancreatic tumor)
showed a low expression whereas Lcc18 (Lcc) (human hindgut carci-
noid) had a higher expression, although lower than controls. A culture
for Mycoplasma was negative for both RIN and Lcc18 whereas BON-
1 was positive and treated for 7 days with Mycoplasma Removal
Agent (MRA) (ICN Biomedicals). After treatment, the BON-1 cells
were checked Mycoplasma-free on culture, DNA staining and DNA
probing. RIN cells were cultured in F12-modi¢ed (Nordcell) medium
supplemented with 1% non-essential amino acids (Biochrom KG) and
10% fetal bovine serum (FBS) (HyClone). To culture BON cells, a 1:1
mixture of F12K (Nordcell) and DMEM (Biochrom KG) medium
was used and supplemented with 5% FBS. Lcc cells were cultured
in RPMI 1640 (Biochrom KG) supplemented with transferrin 0.5%,
insulin 133 I.E./l (Monotard, Novo Nordisk), selenium 0.01%, hydro-
cortisol 0.01%, L-estradiol 0.01% and FBS 5%. All cells received 1%
penicillin-streptomycin and 1% L-glutamine (Biochrom KG). The cells
were housed in an incubator maintaining an atmosphere of 90% hu-
midity and 5.0% CO2 at 37‡C.
2.2. mRNA analysis
Total RNA was isolated from neuroendocrine tumor cell lines [17].
400 Wg was used to isolate mRNA using PolyAtract (Promega) and
examined for PLCB3 expression by a Northern blot analysis. Brie£y,
mRNA was size-fractionated by agarose/formaldehyde gel electropho-
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resis and then transferred to a nylon membrane (Hybond N, Amer-
sham) for analysis. For the detection of PLCB3 mRNA, cDNA ex-
cised from a pBluescript II SK+ plasmid (Stratagene) containing hu-
man PLCB3 cDNA [1] was used as a probe. The probe was labelled
with [K-32P]dCTP (3000 Ci/mmol, Amersham) using the Quick prime
kit (Pharmacia) according to the manufacturer‘s protocol. Membranes
were hybridized overnight in CHURCH bu¡er (7% SDS, 0.5 M
Na2HPO4, 1 mM EDTA and 50% formamide) at 42‡C, then subjected
to a high stringency wash. Storage phosphor screens (Molecular Dy-
namics) were used for exposure. Hybridization signals were quanti¢ed
using a PhosphorImager (Molecular Dynamics). To control for var-
iations in loading and transfer among samples, the PLCB3 signal was
normalized to L-actin signals obtained on the same blot. Results
showed an overexpression of PLCB3 in the clones transfected with
the PLCB3 construct ranging from 5 to 15 times higher than that of
wt and vector only (data not shown).
2.3. Protein analysis
Total cell lysates from the di¡erent clones were prepared and 20 Wg
of protein sample from each clone was analyzed for PLCB3 expres-
sion by Western blotting using an anti-PLCB3 antibody (diluted
1:250) (Santa Cruz Biotechnology). Western blotting and ¢lter devel-
opment were performed as earlier described [18]. Poinceau-red stain-
ing was used as a control for variations in the loading and transfer of
protein. The expression of PLCB3 was estimated to be 15^20 times
higher in the PLCB3-transfected clones compared to the basal wt level
of the respective cell line, except for RIN/PLC: cl. 3 which showed an
approximately ¢ve times higher expression.
2.4. Transfections
For transfections, the encoding region of PLCB3 cDNA [1] was
inserted into the pCEP-4 (vector) plasmid (Invitrogene) using stand-
ard cloning techniques. A vector antisense PLCB3 control (antisense)
was constructed by inserting the encoding region in the antisense
orientation. The antisense reading frame revealed several early stop
codons, thus, would not be translated to any known functional pro-
tein when it was matched against BLAST (NCBI). The di¡erent cell
lines were transfected with vector, antisense and vector-PLCB3 (PLC)
according to the Lipofectin reagent protocol (Life Technologies) and
stable transfectants were selected in hygromycin B (Boehringer Mann-
heim) at a concentration of 400 Wg/ml, 125 Wg/ml and 1.2 mg/ml for
RIN, BON and Lcc, respectively. After clonal expansion, transfec-
tants were maintained at the same selective concentrations and used
at passages 3, 4 and 5 for RIN and BON and at passage 3 for Lcc
clones. The PLCB3 expressing clones (cl.) were named RIN/PLC/cl. 1,
2 and 3, BON/PLC and Lcc/PLC/cl. 1, 2 and 3.
2.5. [3H]thymidine incorporation assay
The RIN cells were used to assess the stability of the test system
and all three expressing clones were used at passages 3, 4 and 5. For
each experiment, 5U104 cells of the wt, controls and PLCB3 express-
ing clone of RIN were seeded in 2 ml of the appropriate medium into
35 mm petri dishes (18 dishes of each). The cell viability was assessed
by trypan blue dye exclusion. After 48, 72 and 96 h, the medium was
changed in six dishes of each cell type and supplemented with 0.2 WCi/
ml [3H]thymidine (Amersham). The RIN cells were allowed to incor-
porate [3H]thymidine for 6 h before they were put on ice for 5 min,
precipitated with 10% ice cold TCA (10 min), washed three times with
ice cold PBS before and ¢nally lysated in 0.3 M NaOH, 1% SDS at
room temperature (20 min). The lysate was transferred to scintillation
tubes containing Optiphase Highsafe II scintillation £uid (Wallac) for
the assessment of L-radiation. The radiation was expressed as disinte-
grations per minute (dpm) (WinSpectral 1414, Wallac). Essentially the
same procedure was repeated for BON and Lcc but due to a longer
doubling time of the two cell lines, the [3H]thymidine incorporation
took place after 48, 96 and 144 h and in the case of BON, the
[3H]thymidine was allowed to incorporate for 12 h.
2.6. Cell counting
Cells were counted at the same respective time points as used for
the [3H]thymidine incorporation assay. 15U103 cells of RIN/PLC: cl
1, 2 and 3, wt and vector were seeded in triplicates onto 24 well plates
(Nunc) at t = 0. When counting, cells were washed once with PBS and
then trypsinized in 0.5 ml of trypsin/EDTA and counted in triplicates,
using a Coulter cell counter. The same procedure was used to count
the BON/PLC clone (20U103 cells/well) and the Lcc/PLC: cl 1
(60U103 cells/well), comparing the growth to respective wt and vector
controls.
2.7. IP3 assay
The PLC activity was investigated by comparing basal levels of
inositol phosphates between RIN wt and RIN/PLC: cl 1 and between
BON wt and BON/PLC (Lcc18 was not investigated as the assay only
could be used for adherent cell lines). 1U106 cells of the di¡erent
clones, in triplicates, were incubated overnight (20 h) with 2 WCi D-
myo[3H]inositol (Amersham) in 2 ml of the appropriate growth me-
dium (cells could not be depleted of FCS without extensive cell death).
The following day, the cells were incubated with medium containing
20 mM LiAc and incubation continued for 15 min at 37‡C. After
washing once with ice cold PBS, 2 ml of acidi¢ed ice cold methanol
was added to each well (methanol/HCl 100:1). The quenched samples
were collected and the dishes were rinsed with an addition of 1 ml of
acidi¢ed methanol. To each sample, 1.5 ml water and 3 ml chloroform
were added. The tubes were mixed vigorously and left on ice for 30
min. The water soluble phase was collected and diluted with two
volumes of water, centrifuged for 5 min and ¢nally, the upper phase
was applied to 0.5 ml AGI-X8 columns (formate form, 100^200
mesh). The samples were washed with 10 ml of 5 mM sodiumtetra-
borate, 60 mM sodiumformate. The total inositol phosphates were
eluted with 5 ml of 0.1 M formic acid and 1.0 M ammonium formate
and subjected to scintillation counting. The chloroform phase samples
containing the phospholipids were dried, redissolved in methanol and
subjected to scintillation counting. The IP3 release was calculated as
the ratio between total inositol phosphates and the total incorporated
D-myo[3H]inositol [19].
2.8. Animals and xenografting
Female balb/c nude mice weighing 20^30 g (Bomholtsgaard) were
housed in cages, fed standard laboratory food and water ad libitum.
They were injected subcutaneous (s.c.) on the hindleg with 2U106
cells in 0.5 ml of the appropriate growth medium. BON/PLC, BON/
wt and BON/vector were injected s.c. in 14 animals in each group.
Lcc/PLC/cl. 1 together with Lcc/wt and Lcc/vector were injected in 18
animals in each group (RIN was not suitable because of its insulin
production). Tumors were allowed to grow for 7 weeks before the
mice were killed. The tumors were thoroughly dissected, weighed,
snap frozen in liquid nitrogen and ¢nally cryosectioned for further
analysis. Approval of this study was obtained from the Uppsala
Ethics Committee for Animal Care and Use (Uppsala, Sweden).
2.9. Immunohistochemistry, antibodies and histology
6 Wm thick cryosections were ¢xed in ice cold acetone for 10 min.
Endogenous peroxidase activity was blocked with 0.3% hydrogen per-
oxide in PBS for 30 min and endogenous avidin binding activity was
blocked by sequential incubation with avidin and biotin for 15 min,
each using a Blocking kit (Vector Laboratories). Unspeci¢c binding of
secondary antibody was blocked by incubation with normal goat se-
rum, diluted 1:5 in PBS. Incubation with the primary antibody was
performed overnight at 4‡C in a humidi¢ed chamber and the sections
were then incubated with biotinylated goat anti-rabbit immunoglobu-
lin (Vector laboratories). The immunoreaction was visualized using a
Vectastain Elite ABC kit (Vector Laboratories) with 3-amino-9-ethyl-
carbazole in dimethylsulfoxide as chromogen and 0.02% hydrogen
peroxide as substrate. Finally, the sections were counterstained with
Mayer’s hematoxylin.
We used a polyclonal chromogranin A rabbit antibody (diluted 1/
2000) to con¢rm that the tumors actually were composed of neuro-
endocrine cells [20]. As a marker for proliferation and malignancy, a
polyclonal Ki-67 antibody (diluted 1/200) (Dakopatts) which reacts
with a nuclear antigen expressed in all phases of the cell cycle except
G0 [16] was used. Sections were analyzed blinded at a 1000U mag-
ni¢cation and positive cells were counted at three di¡erent ‘hot spots’
(de¢ned as areas of maximum number of positive cells compared to
negative cells) using a 1 cm2 grid. The mean percentage of positive
cells of the total cell number was calculated. A pathologist analyzed
the tumors histologically, scoring the abundance of necrosis and the
incidence of capsular invasion (van Gieson as well as hematoxolyn/
eosin staining). Necrosis less than 10% of the tumor area was scored
(+), 10^50% (++) and over 50% (+++).
FEBS 21922 4-5-99
P. Stafilberg et al./FEBS Letters 450 (1999) 210^216 211
2.10. Statistics
All values of mean, range and standard error of the mean (S.E.M.)
were calculated using StatView 4.01 (Abacus Concepts). P values were
calculated using Student’s t-test and considered signi¢cant when
6 0.05.
3. Results
E¡ects on the growth rate in vitro. Three transfected clones
of RIN m5F (RIN/PLC: cl. 1, 2, 3) and Lcc18 (Lcc/PLC: cl.
1, 2, 3) cells, as well as one clone of BON-1 cells (BON/PLC),
were identi¢ed as expressing PLCB3 mRNA. Protein expres-
sion was con¢rmed by Western blots (Fig. 1). As expected, no
protein was detectable in the antisense controls. The PLC
activity measured as IP3 release showed increased levels by
mean 11 and 23% in RIN/PLC: cl. 1 and BON/PLC, respec-
tively, as compared to wt controls. The growth rate, by means
of DNA synthesis, of the PLCB3 expressing clones was com-
pared to that of the three controls (untransfected wt, wt trans-
fected with the vector without an insert (vector) and antisense)
by using the [3H]thymidine incorporation assay. PLCB3 ex-
pressing clones showed growth inhibition at all three time
points chosen for [3H]thymidine incorporation assessment
(Fig. 2). The mean inhibition of RIN/PLC (three clones, seven
passages) at the third time point of measurements compared
to wt, vector and antisense controls were 52% (range 39^86),
38% (21^67) and 33% (3^70), respectively. The BON/PLC
clone (three di¡erent passages) showed a mean growth inhi-
bition of 44% (36^56), 43% (31^56) and 48% (37^64) compared
to wt, vector and antisense controls, respectively. Lcc/PLC: cl
1, 2, 3 (three di¡erent passages) were inhibited by an average
of 77% (71^82) compared to wt and by 58% (57^58) compared
to vector (comparison to antisense was not performed in the
Lcc18 experiments). The growth inhibition was signi¢cant and
reproducible in all experimental series (P value ranging from
0.0001 to 0.05), with the exception of RIN/PLC: cl. 2: pas-
sage 4 compared to the antisense control (P = 0.656), with a
very low variation between samples within the individual ex-
periments (S.E.M., mean 4.8%, range 0.5^21.7%) (Table 1).
Cell counting was performed comparing the PLCB3 express-
ing clones of RIN, BON and Lcc/PLC: cl. 1 to respective wt
and the vector control. Growth inhibition was recorded in the
PLCB3 expressing clones with a mean ¢nal reduction in the
cell number compared to wt of 50% (range 43^60%) for RIN/
PLC (three clones), 38% (range 33^42%) for BON/PLC and
48% (range 44^51%) for Lcc/PLC: cl. 1. No growth inhibition
by means of a reduced cell number was seen for the vector
controls (Fig. 2). The PLCB3-transfected clones of the adher-
ent cell lines RIN m5F and BON-1 seemed to exhibit some
morphological changes when cultured in vitro. wt and vector
controls showed dendritic expansions and formed a homoge-
nous cell layer, whereas the PLCB3 expressing clones tended
to grow in colonies and were more rounded up.
Tumor formation in nude mice and phenotype changes.
BON/PLC and Lcc/PLC: cl. 1 cell clones as well as respective
wt and vector controls were xenografted to altogether 96 nude
mice. The transplants were left to grow for 7 weeks. A tumor
take was obtained in 12/14 mice xenografted with BON/PLC
and BON/wt, 11/14 with BON/vector, 14/18 animals harbor-
ing the Lcc/PLC: cl. 1 and 17/18 in the mice transplanted with
Lcc/ : wt and Lcc/vector. During dissection of the tumors, a
substantial di¡erence of invasiveness was macroscopically ob-
served. None of the tumors formed by PLCB3 expressing
clones showed macroscopic signs of invasion and all seemed
to be surrounded by intact capsules whereas 33% of BON/wt
and 83% of Lcc/wt mice tumors as well as 67% of the Lcc/
vector and 76% of the BON/vector tumors grew invasively
into the surrounding soft tissue. The tumor weight was sig-
ni¢cantly lower (P6 0.01) in Lcc/PLC: cl. 1 compared to wt
and vector. BON/PLC tumors, however, showed no weight
di¡erence compared to controls (Fig. 3). Immunohistochem-
ical staining for chromogranin A (CgA) con¢rmed the neuro-
endocrine status of the formed tumors. Staining for prolifer-
ation marker Ki-67 indicated a signi¢cant (P6 0.001)
decrease in the number of proliferating cells in the PLCB3
expressing tumors of both BON-1 and Lcc18 compared to
wt and vector. BON/PLC tumors displayed 21 þ 2 (S.D.)%
Ki67 positive cells, BON/wt showed a positive cell count of
73 þ 1 (S.D.)% and BON/vector of 51 þ 2 (S.D.)%. Ki-67
staining was positive in 23 þ 5 (S.D.)% of the cells in the
tumors formed by Lcc/PLC: cl. 1 and in 51 þ 5 (S.D.)% and
50 þ 2 (S.D.)% of cells from Lcc/wt and Lcc/vector xenografts,
respectively (Fig. 4). Microscopic examination showed inva-
sive growth in 4/12 BON/wt tumors whereas none of the vec-
tor or BON/PLC tumors revealed such features. However,
only seven BON/wt and two BON/PLC specimens could ac-
tually be accurately scored, due to incomplete capsular mate-
rial included on the slides provided for the pathologist. Ne-
crosis was abundant (s 50%) in 7/12 BON/PLC, 3/12 BON/
wt and 6/12 BON/vector tumors. Intermediate necrosis (10^
50%) was found in 2/12 of the lesions formed by BON/PLC, 4/
12 of BON/wt and 5/12 BON/vector tumors. Less than 10%
necrosis was observed in 3/12, 5/12 and 1/12 in the tumors
consisting of BON/PLC, BON/wt and BON/vector cell clones,
respectively. The material was too limited for accurate scoring
of capsular microinvasion in the Lcc18 xenografts, but thor-
ough assessments of necrosis revealed no signi¢cant di¡eren-
ces between Lcc/PLC and controls.
Fig. 1. Western blot for PLCB3. Lane 1: wt, lane 2: vector and
lane 3: antisense. a: RIN m5F, lanes 4^6: PLCB3 clones 1^3. b:
BON-1, lane 4: PLCB3. c, Lcc18, lanes 4^6: PLCB3 clones 1^3.
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4. Discussion
We have found that the restoration of PLCB3 expression in
neuroendocrine tumor cell lines substantially inhibits the
growth rate and suppresses the neoplastic phenotype both in
vitro and in vivo, suggesting that PLCB3 may be important in
the neuroendocrine tumorigenesis. The PLCB3-transfected
clones revealed increased levels of IP3 compared to wt con-
trols when grown with serum. Measurement of IP3 is an es-
tablished method to verify PLC-mediated intracellular signal-
ing [19]. Since a complete depletion of serum is fatal to the
neuroendocrine cell lines, we performed the IP3 assay with
serum present in the medium. Growth factors and G-protein
activators in the serum lead to continuous intracellular signal-
ing in the cell lines. This might explain why the di¡erence in
IP3 levels between the PLCB3 expressing clones and their wt
Fig. 2. Graphs visualizing the mean [3H]thymidine uptake (A^C), measured as dpm and cell number (D^F). PLCB3 expressing clones show a
signi¢cantly reduced [3H]thymidine uptake compared to controls (wt, vector and antisense) as well as a signi¢cantly reduced cell number.
Graphs showing individual experiments. Bars: S.E.M. A: RIN m5F with RIN/PLC: cl 3 passage 5. B: BON-1 with BON/PLC passage 5. C:
Lcc18 with Lcc/PLC: cl 3 passage 3. D: RIN m5F with RIN/PLC: cl 1. E: BON-1 with BON/PLC. F: Lcc18 with Lcc/PLC: cl 1.
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controls is relatively moderate, however obvious. The increase
of IP3 in the transfected clones possibly re£ects an increase of
the PLC activity due to the transfected PLCB3 construct.
[3H]thymidine incorporation is a reliable and reproducible
method for the assessment of cell growth and re£ects both
the cell number and DNA synthesis rate [15]. Together with
the reduced growth rate by the cell number and the reduced
tumor weight in vivo for Lcc/PLC: cl. 1, our experiments
show that induction of PLCB3 expression by transfection sig-
ni¢cantly reduces the growth rate in three di¡erent neuroen-
docrine tumor cell lines which lack endogenous PLCB3 ex-
pression. The highly signi¢cant reduction of the [3H]thymidine
uptake compared to wt, vector and antisense controls was
reproducible in 12/13 experimental series and showed a very
low internal variation. Interestingly, the vector, to some ex-
tent, seems to impair the DNA synthesis recorded as reduced
thymidine incorporation but does not, according to the results
from cell counting, inhibit the cell growth. We have no indi-
cation that the construct per se produces toxic e¡ects leading
to cell death, as the clones could be kept alive for over 15
months and were able to grow in nude mice. Instead, PLCB3
expressing xenografts reveal morphological features suggest-
ing that PLCB3 is capable of altering the neoplastic pheno-
type.
Suppression of the growth in vivo by means of a signi¢-
cantly lowered tumor weight was observed for Lcc/PLC: cl 1
compared to controls but not for BON/PLC, which could be
explained by a lower proliferation rate of the BON-1 cell line
making di¡erences more di⁄cult to observe. However, a sig-
ni¢cantly smaller proportion of proliferating Ki-67 positive
tumor cells was observed in both BON/PLC and Lcc/PLC:
cl 1 compared to controls, which indicate that the prolifera-
tion rate and the malignant phenotype were suppressed [16].
Although the mechanism remains to be explained, other ob-
servations, such as a lack of macroscopic signs of invasive
behavior in vivo, support the interpretation that PLCB3
may induce phenotypic changes. Unfortunately, the incom-
plete microscopic examination of the xenografted BON-1 tu-
mors failed to support the macroscopic ¢ndings of a more
non-invasive behavior of the PLCB3 expressing tumors. The
amount of necrosis was higher in both the vector control and
the PLCB3 expressing tumors of BON-1. This might be an
e¡ect of the plasmid vector itself. The proliferation rate by
means of Ki-67 positive cells was, however, equally abundant
in the wt tumors as in the vector controls. In consistency with
interpretation principles applied in other suppressor gene
studies, our ¢ndings support that PLCB3 might harbor sup-
pressor characteristics [21].
It has been shown that PLCB1 activates PKC which in turn
activates raf via a p21ras-independent mechanism [11]. The
dependency on the di¡erent pathways for mitogenic signaling
seems to di¡er between cell systems and it might be that the
loss of PLCB3 function only a¡ects the di¡erentiation and
growth regulation in certain cell types. It has been reported
that PLCB4 becomes upregulated upon introduction of wt
p53 into p53 de¢cient mouse M1 myeloid leukemia cells.
This ¢nding may suggest that PLCB4 comprises a down-
stream target in mediating the apoptotic e¡ect of p53 [22].
Sequencing of PLCB3 in neuroendocrine tumors has not re-
vealed mutations [23] but silencing by hypermethylation or
imprinting has not yet been excluded [24,25]. Homozygous
inactivation of the Plcb3 gene in mice resulted in early embry-
onic lethality. No increased incidence of tumors was observed
in mice heterozygous for Plcb3, however, challenging of the
Fig. 3. Weight (g) of xenografted tumors. A: BON-1. B: Lcc18.
Black stacks: tumors formed by PLCB3-transfected clones. White
stacks: wt cells. Gray stacks: tumors consisting of cell clones trans-
fected with the vector control. Bars: S.E.M.
Table 1
DNA synthesis rate of PLCB3 expressing clones compared to wt, vector and antisense
PLCB3 wt Vector Antisense Passage
number
Statistical signi¢cance in [3H]thymidin
uptake for PLCB3 versus:
wt Vector Antisense
RIN 5 642 þ 61 cl. 1 1 0075 þ 1048 7 591 þ 225 8 715 þ 343 4 P6 0.01 P6 0.001 P6 0.001
667 þ 87 cl. 2 4 765 þ 270 2 013 þ 437 2 219 þ 319 3 P = 0.0001 P6 0.05 P6 0.01
3 700 þ 177 cl. 2 6 058 þ 175 4 685 þ 162 3 830 þ 184 4 P6 0.001 P6 0.01 P = 0.656
4 100 þ 66 cl. 2 6 888 þ 209 8 354 þ 621 5 732 þ 284 5 P = 0.0001 P6 0.001 P6 0.01
3 504 þ 164 cl. 3 6 292 þ 259 4 547 þ 151 5 699 þ 341 3 P6 0.001 P6 0.01 P6 0.01
4 306 þ 152 cl. 3 9 496 þ 58 7 488 þ 364 5 752 þ 293 4 P = 0.0001 P6 0.001 P6 0.01
5 714 þ 494 cl. 3 12 299 þ 408 8 562 þ 122 8 474 þ 380 5 P6 0.01 P6 0.01 P6 0.01
BON 279 040 þ 4 945 cl. 1 436 381 þ 5 280 401 742 þ 4 365 383 300 þ 5 162 3 P = 0.0001 P6 0.001 P6 0.01
146 916 þ 1 713 cl. 1 248 040 þ 8 472 248 792 þ 17 846 309 244 þ 7 533 4 P6 0.07 P6 0.01 P = 0.0001
109 192 þ 6 567 cl. 1 248 040 þ 7 888 249 214 þ 17 109 304 838 þ 9 798 5 P = 0.0001 P = 0.0001 P = 0.0001
Lcc 1 437 þ 57 cl. 1 6 843 þ 161 3 421 þ 275 3 P6 0.001 P6 0.05
1 235 þ 11 cl. 2 6 779 þ 265 2 969 þ 258 3 P6 0.01 P6 0.05
1 979 þ 90 cl. 3 6 937 þ 206 4 793 þ 355 3 P6 0.01 P6 0.05
Mean of dpm þ S.E.M. at the third timepoint for [3H]thymidine incorporation. Signi¢cant di¡erences were between PLCB3 expressing clones
and wt, vector and antisense, respectively. Passages are numbered. Clone 1: cl. 1, clone 2: cl. 2 and clone 3: cl. 3
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heterozygous mice with chemical carcinogens might reveal a
haploid insu⁄ciency as they express lower levels of Plcb3 than
their wt littermates [26,27]. Further, one might speculate
whether a homozygous inactivation of the MEN 1 gene [4]
in neuroendocrine tumors could result in the downregulation
of PLCB3 expression and a¡ect a previously unknown global
tumor suppressor pathway. In conclusion, the data presented
here do imply that PLCB3 may be involved in the neuroendo-
crine tumorigenesis and have properties of a tumor suppressor
gene.
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